Edwin DeJesus

19.2k total citations · 5 hit papers
149 papers, 9.8k citations indexed

About

Edwin DeJesus is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Edwin DeJesus has authored 149 papers receiving a total of 9.8k indexed citations (citations by other indexed papers that have themselves been cited), including 136 papers in Infectious Diseases, 119 papers in Virology and 39 papers in Emergency Medicine. Recurrent topics in Edwin DeJesus's work include HIV/AIDS drug development and treatment (134 papers), HIV Research and Treatment (119 papers) and HIV/AIDS Research and Interventions (68 papers). Edwin DeJesus is often cited by papers focused on HIV/AIDS drug development and treatment (134 papers), HIV Research and Treatment (119 papers) and HIV/AIDS Research and Interventions (68 papers). Edwin DeJesus collaborates with scholars based in United States, United Kingdom and Germany. Edwin DeJesus's co-authors include Andrew Cheng, Joel E. Gallant, Anton Pozniak, Damian J. McColl, Jeffrey Enejosa, José Ramón Arribas, Adriano Lazzarin, John J. Toole, Peter Ruane and Kirsten White and has published in prestigious journals such as New England Journal of Medicine, The Lancet and PLoS ONE.

In The Last Decade

Edwin DeJesus

147 papers receiving 9.5k citations

Hit Papers

Tenofovir DF, Emtricitabi... 2006 2026 2012 2019 2006 2008 2009 2017 2022 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
    2006 703 citations Joel E. Gallant, Edwin DeJesus et al. profile →
  2. Maraviroc for Previously Treated Patients with R5 HIV-1 Infection
    2008 570 citations Edwin DeJesus et al. profile →
  3. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
    2009 478 citations Edwin DeJesus, Peter Sklar et al. profile →
  4. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
    2017 278 citations Anton Pozniak, Ellen Koenig et al. profile →
  5. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
    2022 164 citations Sorana Segal‐Maurer, Edwin DeJesus et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Edwin DeJesus 8.3k 6.6k 2.4k 1.9k 969 149 9.8k
Donna M. Jacobsen 9.1k 1.1× 7.0k 1.1× 1.8k 0.8× 2.6k 1.3× 665 0.7× 33 10.6k
Patrick Yéni 6.8k 0.8× 5.3k 0.8× 1.7k 0.7× 2.1k 1.1× 519 0.5× 89 8.5k
David A. Cooper 5.5k 0.7× 4.4k 0.7× 1.4k 0.6× 1.6k 0.8× 633 0.7× 118 7.1k
José M. Gatell 10.3k 1.2× 8.0k 1.2× 3.4k 1.4× 3.3k 1.7× 951 1.0× 218 13.5k
Graeme Moyle 4.9k 0.6× 3.8k 0.6× 2.4k 1.0× 1.5k 0.8× 458 0.5× 217 6.9k
Schlomo Staszewski 6.1k 0.7× 5.1k 0.8× 1.6k 0.7× 1.5k 0.8× 378 0.4× 115 7.3k
Gilles Peytavin 4.8k 0.6× 3.7k 0.6× 872 0.4× 1.2k 0.6× 618 0.6× 267 6.3k
Kathleen Squires 5.1k 0.6× 4.4k 0.7× 1.3k 0.5× 1.6k 0.9× 327 0.3× 80 6.9k
Andrew Zolopa 5.6k 0.7× 3.6k 0.6× 1.3k 0.5× 1.9k 1.0× 310 0.3× 107 6.9k
Chloe Orkin 3.8k 0.5× 2.7k 0.4× 1.8k 0.7× 1.8k 1.0× 885 0.9× 168 6.0k

Countries citing papers authored by Edwin DeJesus

Since Specialization
Citations

This map shows the geographic impact of Edwin DeJesus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edwin DeJesus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edwin DeJesus more than expected).

Fields of papers citing papers by Edwin DeJesus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edwin DeJesus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edwin DeJesus. The network helps show where Edwin DeJesus may publish in the future.

Co-authorship network of co-authors of Edwin DeJesus

This figure shows the co-authorship network connecting the top 25 collaborators of Edwin DeJesus. A scholar is included among the top collaborators of Edwin DeJesus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edwin DeJesus. Edwin DeJesus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Eron, Joseph J., Paul Cook, Megha Mehrotra, et al.. (2025). Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab. The Journal of Infectious Diseases. 231(6). 1440–1444. 1 indexed citations
2.
Riddler, Sharon A., Constance A. Benson, Steven G. Deeks, et al.. (2024). A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist Vesatolimod. Infectious Diseases and Therapy. 13(11). 2285–2299. 1 indexed citations
3.
Eron, Joseph J., Moti Ramgopal, Olayemi Osiyemi, et al.. (2024). Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV‐1 and end‐stage kidney disease on chronic haemodialysis. HIV Medicine. 26(2). 302–307.
4.
5.
DeJesus, Edwin, Jean‐Michel Molina, Yazdan Yazdanpanah, et al.. (2020). Islatravir safety analysis through week 48 from a phase 2 trial in treatment naive adults with HIV-1 infection. Journal of the International AIDS Society. 2 indexed citations
6.
DeJesus, Edwin, Sorana Segal‐Maurer, Moti Ramgopal, et al.. (2018). Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment. AIDS Research and Human Retroviruses. 34(4). 337–342. 67 indexed citations
7.
DeJesus, Edwin, Anton Pozniak, Melanie Thompson, et al.. (2015). P031: Tenofovir alafenamide in a single-tablet regimen in initial HIV-1 therapy. Journal of the International AIDS Society. 18(3 (Suppl 2)). 9 indexed citations
8.
DeJesus, Edwin, Michael T. Yin, Frank Post, et al.. (2015). P030: Renal and bone safety of tenofovir alafenamide versus tenofovir disoproxil fumarate. Journal of the International AIDS Society. 18(3 (Suppl 2)). 9 indexed citations
9.
DeJesus, Edwin, et al.. (2014). P24: Long-term efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir plus ritonavir plus emtricitabine/tenofovir. Journal of the International AIDS Society. 17(2(Suppl 1)). 1 indexed citations
10.
Gallant, Joel E., Ellen Koenig, Jaime Andrade‐Villanueva, et al.. (2013). Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results. The Journal of Infectious Diseases. 208(1). 32–39. 84 indexed citations
11.
Ross, Lisa, Winkler G. Weinberg, Edwin DeJesus, et al.. (2010). Impact of Low Abundance HIV Variants on Response to Ritonavir-Boosted Atazanavir or Fosamprenavir Given Once Daily with Tenofovir/Emtricitabine in Antiretroviral-Naive HIV-Infected Patients. AIDS Research and Human Retroviruses. 26(4). 407–417. 8 indexed citations
12.
Hodder, Sally, Karam Mounzer, Edwin DeJesus, et al.. (2010). Patient-Reported Outcomes in Virologically Suppressed, HIV-1–Infected Subjects After Switching to a Simplified, Single-Tablet Regimen of Efavirenz, Emtricitabine, and Tenofovir DF. AIDS Patient Care and STDs. 24(2). 87–96. 67 indexed citations
13.
14.
Hicks, Charles B., Edwin DeJesus, Louis Sloan, et al.. (2009). Comparison of Once-Daily Fosamprenavir Boosted with Either 100 or 200 mg of Ritonavir, in Combination with Abacavir/Lamivudine: 96-Week Results from COL100758. AIDS Research and Human Retroviruses. 25(4). 395–403. 17 indexed citations
15.
Jacobson, Jeffrey M., Daniel R. Kuritzkes, Eliot Godofsky, et al.. (2008). Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected Adults. Antimicrobial Agents and Chemotherapy. 53(2). 450–457. 125 indexed citations
16.
DeJesus, Edwin. (2008). 96-Week Efficacy/Safety Data Comparing Two Doses of Ritonavir (/r) to Boost Once-Daily (QD) Fosamprenavir (FPV), Used in Combination with Abacavir (ABC)/Lamivudine (3TC). 46th Annual Meeting. 3 indexed citations
17.
DeJesus, Edwin. (2008). Elvucitabine Phase II 48 Week Interim Results Show Safety and Efficacy Profiles Similar to Lamivudine in Treatment Naive HIV-1 Infected Patients with a Unique Pharmacokinetic Profile. 46th Annual Meeting. 3 indexed citations
18.
Rockstroh, Jürgen K., Edwin DeJesus, Cynthia Wat, et al.. (2008). Adherence to Enfuvirtide and Its Impact on Treatment Efficacy. AIDS Research and Human Retroviruses. 24(2). 141–148. 4 indexed citations
19.
Elion, Richard, et al.. (2007). Advances in HIV therapeutics: news from the 4th International AIDS Society Conference.. PubMed. 17(10). 484–90. 2 indexed citations
20.
Pozniak, Anton, Joel E. Gallant, Edwin DeJesus, et al.. (2006). Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 43(5). 535–540. 184 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Donna M. Jacobsen Breakdown of academic impact, for papers by Patrick Yéni Breakdown of academic impact, for papers by David A. Cooper Breakdown of academic impact, for papers by José M. Gatell Breakdown of academic impact, for papers by Graeme Moyle Breakdown of academic impact, for papers by Schlomo Staszewski Breakdown of academic impact, for papers by Gilles Peytavin Breakdown of academic impact, for papers by Kathleen Squires Breakdown of academic impact, for papers by Andrew Zolopa Breakdown of academic impact, for papers by Chloe Orkin
Rankless by CCL
2026